ANANI Pharmaceuticals, Inc. ANIP · NASDAQ
$72.67 +0.15% (+$0.11)
- Market cap
- $1.67B
- Enterprise value
- $1.64B
- P/E
- 15.7x
- Forward P/E
- 8.5x
- PEG
- -
- P/S
- 1.7x
- P/FCF
- 10.4x
- EV/EBITDA
- 6.4x
- ROIC
- 9.3%
- Gross margin
- 65.2%
- Net margin
- 10.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -0.1x
- Beta
- 0.50
- Free float
- 85.7%
About the company
ANI Pharmaceuticals, Inc. (ANI) is an American pharmaceutical company specializing in the development, manufacturing, and sale of generic and specialty pharmaceuticals. With a broad portfolio of pharmaceutical products, including generic versions of drug substances and specialty drugs for various therapeutic indications, ANI Pharmaceuticals is a recognized player in the pharmaceutical market. The company focuses on providing affordable and quality medicines for patients and healthcare facilities across the United States. ANI Pharmaceuticals also invests in research and development of new pharmaceutical products and seeks opportunities to expand its portfolio through acquisitions and licenses. ANI Pharmaceuticals, Inc. (ANI) shares could be suitable for investors seeking investment opportunities in the pharmaceutical industry and generic drugs.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Nikhil Lalwani
Employees
970
Headquarters
Baudette
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number